Fuda Cancer Hospital
Ewing's sarcoma treatment cost in China typically runs from $75,000 to $140,000 for complex multimodal care. Essential diagnostics like a complete blood count range from $100 to $100, while primary radiation therapy for sarcomas costs $10,500 to $21,700. Total expenses depend on the treatment stage, surgical technology, and clinic tier. Patients often save 50% to 70% compared to the United States. Top treatment hubs include Guangzhou, Shanghai, and Beijing.
Typical Ewing's Sarcoma Treatment Costs in China
Bookimed Expert Insight: Patients with advanced or late-stage Ewing's sarcoma benefit from multidisciplinary care at JCI-accredited centers. Fuda Cancer Hospital in Guangzhou specializes in minimally invasive alternatives to standard chemotherapy, utilizing technologies like NanoKnife and cryosurgery. For those requiring precision radiation, expert-led teams provide IMRT and VMAT protocols. Choosing centers with high international patient volumes ensures access to coordinated, multi-step regimens at competitive rates.
| China | Turkey | Austria | |
| Sarcoma surgery | from $16,500 | from $10,000 | from $35,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Radiation Therapy for Sarcomas | from $10,500 | from $3,250 | from $18,000 |
| Complex treatment of Ewing's sarcoma | from $75,000 | from $30,000 | from $55,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Ewing's sarcoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Ewing's sarcoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Ewing's sarcoma treatment journey.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.
Ewing sarcoma treatment in China follows a multimodal protocol of systemic chemotherapy, surgical resection, and radiation therapy. Chinese centers utilize international standards from the Chinese Society of Clinical Oncology. Specific regimens include alternating VDC and IE chemotherapy cycles to target the primary tumor and micrometastases.
Bookimed Expert Insight: While major centers follow international guidelines, JCI-accredited facilities like Fuda Cancer Hospital offer unique minimally invasive alternatives. They utilize technologies like NanoKnife and cryosurgery for advanced cases. This allows for localized tumor destruction in patients who cannot tolerate traditional aggressive surgery or high-dose chemotherapy cycles.
Patient Consensus: Patients emphasize traveling to high-volume metropolitan centers for accurate pathology and molecular testing. They note that starting neoadjuvant chemotherapy quickly is vital given the aggressive nature of this sarcoma.
China offers advanced local therapies for sarcomas. These include cryosurgery, NanoKnife, and carbon ion radiotherapy. Specialized centers utilize High-Intensity Focused Ultrasound (HIFU) for non-invasive treatment. These techniques target complex tumors while preserving healthy tissue and critical structures near the tumor site.
Bookimed Expert Insight: Fuda Cancer Hospital stands out for managing late-stage cases using unique combinations. They integrate cryosurgery with vascular interventional therapy for difficult tumors. This approach is particularly valuable for patients from over 100 countries. It serves those whose tumors are considered unresectable in other regions.
Patient Consensus: Patients value the availability of proton therapy for protecting the spine and pelvis. They emphasize that the best results come from teams combining orthopedic oncology with reconstruction specialists.
Top hospitals in China for Ewing's sarcoma include elite institutions like Fuda Cancer Hospital and Beijing Jishuitan Hospital. Specialized centers focus on limb-sparing operations and advanced radiation. These facilities maintain Joint Commission International (JCI) accreditation. They utilize multidisciplinary teams for coordinated chemotherapy, surgery, and radiotherapy protocols.
Bookimed Expert Insight: Coordination between pediatric and orthopedic departments is the strongest quality signal in Chinese centers. Fuda Cancer Hospital manages over 30,000 international patients by offering over 10 types of minimally invasive therapies. This specialized focus on non-systemic treatments provides options for cases where traditional heavy chemotherapy is difficult.
Patient Consensus: Patients emphasize finding a dedicated orthopedic oncology unit rather than a general hospital. They warn that initial biopsy planning is critical to ensuring limb-sparing surgery remains possible later.
Verify Chinese medical quality by confirming a facility Tier 3A (Sanjia) status. This government ranking represents the highest level of safety and technology. Look for Joint Commission International (JCI) accreditation and doctors with Senior Physician (Zhuren Yishi) titles for complex sarcoma care.
Bookimed Expert Insight: Look beyond general cancer volume to find specialized leaders. Professor Dr. Liu Shi Xin at Xiamen Humanity Hospital holds elite State Council honors. This designation is rarer and more significant than standard hospital rankings for complex Ewing's sarcoma cases.
Patient Consensus: Patients emphasize asking for the team’s specific experience with primary bone sarcomas. They recommend getting a written multidisciplinary plan including chemotherapy and radiation before traveling.
Chinese oncology centers often integrate Traditional Chinese Medicine (TCM) with Western protocols. Integrated therapies focus on managing side effects. JCI-accredited facilities like Fuda Cancer Hospital use complementary techniques. These support recovery during bone resection and chemotherapy. Always coordinate with your specialist oncology team first.
Bookimed Expert Insight: Top Chinese oncology centers often focus on biological synergy. Fuda Cancer Hospital uses minimally invasive therapies like NanoKnife alongside TCM. This combination aims to manage advanced stages where standard chemo is difficult. Our data shows patients choose China specifically for this integrative multi-technology approach.
Patient Consensus: Patients emphasize using TCM only for comfort and appetite during treatment. They warn that herbs should never replace surgery or radiation for aggressive sarcomas.